Company Description
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States.
The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone.
It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances.
In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications.
Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients.
Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Sep 16, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Frank Heuszel |
Contact Details
Address: 1400 Broadfield Blvd., Suite 130 Houston, Texas 77084 United States | |
| Phone | 281 415 6576 |
| Website | impactbiomedinc.com |
Stock Details
| Ticker Symbol | IBO |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $3.00 |
| CIK Code | 1834105 |
| CUSIP Number | 45259L205 |
| ISIN Number | US45259L2051 |
| Employer ID | 85-3926944 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Frank D. Heuszel Esq., J.D. | Chairman and Chief Executive Officer |
| Mark J. Suseck | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 11, 2026 | 10-K | Annual Report |
| Mar 4, 2026 | 8-K | Current Report |
| Dec 30, 2025 | DEF 14C | Filing |
| Dec 11, 2025 | PRE 14C | Filing |
| Nov 7, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | 8-K | Current Report |
| Oct 27, 2025 | 8-K | Current Report |
| Sep 22, 2025 | DEF 14A | Other definitive proxy statements |
| Sep 9, 2025 | DEF 14C | Filing |
| Aug 25, 2025 | PRE 14C | Filing |